ERBB2 and cancer: For example, the luminal B subtype cancers are treated with endocrine therapies in combination with ERBB2 targeted drugs [9, 10], because the crosstalk between ER and ERBB2 can lead to endocrine therapy resistance [11–14], while ERBB2-positive subtype tumors can benefit from ERBB2 targeted drugs [15–19].